Arax Advisory Partners’s SpringWorks Therapeutics SWTX Stock Holding History

Arax Advisory Partners’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-11	Closed	-$517	–	4233
2025 Q2	$517	Sell	11 -11	-50%	-$489	﹤0.01%	2927
2025 Q1	$972	Sell	22 -45	-67%	-$2.07K	﹤0.01%	2314
2024 Q4	$2.42K	Sell	67 -8	-11%	-$280	﹤0.01%	1964
2024 Q3	$2.4K	Sell	75 -6	-7%	-$224	﹤0.01%	1996
2024 Q2	$3.05K	Buy	+81	New	+$3.41K	﹤0.01%	1813

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Arax Advisory Partners's SWTX Position: Q3 2025 in Review

Arax Advisory Partners sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 11 shares — an estimated $517 sold.

Arax Advisory Partners first reported a position in SWTX in Q2 2024 and held it in 5 quarters. The position peaked at $3.05K in Q2 2024. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Arax Advisory Partners reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Arax Advisory Partners sold 11 SpringWorks Therapeutics shares in Q3 2025, an estimated $517.
Arax Advisory Partners first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 5 quarters.
Arax Advisory Partners's SpringWorks Therapeutics position peaked at $3.05K in Q2 2024.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Arax Advisory Partners's 13F filing for Q3 2025, filed 14 Nov 2025.